PE20020572A1 - Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos - Google Patents
Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicosInfo
- Publication number
- PE20020572A1 PE20020572A1 PE2001001202A PE2001001202A PE20020572A1 PE 20020572 A1 PE20020572 A1 PE 20020572A1 PE 2001001202 A PE2001001202 A PE 2001001202A PE 2001001202 A PE2001001202 A PE 2001001202A PE 20020572 A1 PE20020572 A1 PE 20020572A1
- Authority
- PE
- Peru
- Prior art keywords
- antigens
- compositions
- istimation
- chemicione
- cytocine
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 230000005847 immunogenicity Effects 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 239000002671 adjuvant Substances 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108010030416 proteoliposomes Proteins 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 150000002270 gangliosides Chemical class 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION INMUNOGENICA QUE COMPRENDE: a) UNO O MAS ANTIGENOS INMUNOGENICOS; b) UN VEHICULO QUE CONSISTE EN PROTEOLIPOSOMAS DERIVADOS DEL COMPLEJO DE PROTEINAS DE LA MEMBRANA EXTERNA DE UNA BACTERIA GRAM-NEGATIVA (NEISSERIA MENINGITIDIS) LOS CUALES CONTIENEN GANGLIOSIDOS INCORPORADOS Y c) ADYUVANTES. LOS ANTIGENOS PUEDEN SER PEPTIDOS, POLIPEPTIDOS, PROTEINAS, SUS CORRESPONDIENTES SECUENCIAS DE ADN, CELULAS O SUS LISADOS Y PROTEOLIPOSOMAS (VSSP) FORMADOS AL UNIR EL COMPLEJO DE PROTEINAS DE LA MEMBRANA EXTERNA (CPME) DE NEISSERIA MENINGITIDIS CON GANGLIOSIDOS MEDIANTE ENLACES HIDROFOBOS. ESTAS COMPOSICIONES PUEDEN FORMULARSE SOLAS O FORMANDO EMULSIONES CON EL ADYUVANTE DE NATURALEZA OLEOSA SELECCIONADO DE UN POLIPEPTIDO NATURAL O RECOMBINANTE O EL ADYUVANTE INCOMPLETO DE FREUND (AIF), UNA CITOCINA O UNA QUIMICIONA DONDE LA CITOCINA ES EL FACTOR DE ESTIMULACION DE COLONIAS DE GRANULOCITOS Y MACROFAGOS. LAS COMPOSICIONES PERMITEN HACER ANTIGENOS DE MUY BAJA INMUNOGENICIDAD, TALES COMO RECEPTORES DE FACTORES DE CRECIMIENTO SIN NECESIDAD DE RECURRIR A CAMBIOS ESTRUCTURALES EN LOS MISMOS. EN PARTICULAR MUESTRA COMO PREPARAR COMPOSICIONES INMUNOESTIMULADORAS CAPACES DE GENERAR RESPUESTAS INMUNES ESPECIFICAS INCLUSO EN HUESPEDES INMUNOCOMPROMOMETIDOS COMO LOS QUE PADECEN DE CANCER E INFECCIONES DE ORIGEN VIRAL O BACTERIANAS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20000285A CU23000A1 (es) | 2000-12-06 | 2000-12-06 | Composiciones vacunales para la inmunoterapia activa específica del cáncer |
| CU20010167A CU23009A1 (es) | 2001-07-12 | 2001-07-12 | Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020572A1 true PE20020572A1 (es) | 2002-07-31 |
Family
ID=38812545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001001202A PE20020572A1 (es) | 2000-12-06 | 2001-11-29 | Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7776342B2 (es) |
| EP (1) | EP1356822B1 (es) |
| JP (1) | JP4210519B2 (es) |
| KR (1) | KR100850473B1 (es) |
| CN (1) | CN1291755C (es) |
| AR (1) | AR031638A1 (es) |
| AT (1) | ATE485833T1 (es) |
| AU (2) | AU2151902A (es) |
| BR (1) | BRPI0116013B8 (es) |
| CA (1) | CA2431188C (es) |
| DE (1) | DE60143363D1 (es) |
| DK (1) | DK1356822T3 (es) |
| EA (1) | EA005138B1 (es) |
| HK (1) | HK1063726A1 (es) |
| MX (1) | MXPA03005032A (es) |
| NZ (1) | NZ526282A (es) |
| PE (1) | PE20020572A1 (es) |
| UY (1) | UY27059A1 (es) |
| WO (1) | WO2002045746A2 (es) |
| ZA (1) | ZA200304411B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1367395A1 (de) * | 2002-05-02 | 2003-12-03 | B.R.A.H.M.S Aktiengesellschaft | Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern |
| EP1358910A1 (de) * | 2002-05-02 | 2003-11-05 | B.R.A.H.M.S Aktiengesellschaft | Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen |
| CU23257A1 (es) * | 2003-02-27 | 2008-01-24 | Centro Inmunologia Molecular | COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA |
| AR045815A1 (es) * | 2003-10-09 | 2005-11-16 | Ct Ingenieria Genetica Biotech | Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano |
| WO2005111079A2 (en) * | 2004-05-14 | 2005-11-24 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41 |
| CA2728374A1 (en) * | 2008-06-17 | 2010-01-14 | Universite Laval | Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines |
| RU2606855C2 (ru) * | 2010-12-22 | 2017-01-10 | Байер Интеллектчуал Проперти Гмбх | Повышение иммунного отклика у видов крупного рогатого скота |
| KR101323845B1 (ko) * | 2011-01-21 | 2013-10-31 | 광주과학기술원 | 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물 |
| CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
| RU2747857C2 (ru) * | 2013-03-15 | 2021-05-17 | Ин3Био Лтд. | Самособирающиеся синтетические белки |
| CU24299B1 (es) * | 2013-08-02 | 2017-12-08 | Centro De Inmunología Molecular | Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico |
| HK1194912A2 (en) * | 2013-09-17 | 2014-10-24 | Bestop Group Holdings Ltd | Growth factor concentrate and the use thereof |
| US10105306B2 (en) * | 2013-09-17 | 2018-10-23 | Bestop Group Holdings Limited | Method of preparing a growth factor concentrate |
| US10087226B2 (en) * | 2014-03-11 | 2018-10-02 | Universite D'aix-Marseille | Chimeric peptide that interacts with cell membrane gangliosides |
| EP3597214A1 (en) | 2017-03-15 | 2020-01-22 | Centro de Inmunologia Molecular | Method for the treatment of patients with carcinomas |
| CA3076012A1 (en) * | 2017-09-27 | 2019-04-04 | L2 Diagnostics, Llc | Erbb peptide pharmaceutical and vaccine compositions and therapeutics uses thereof for cancer |
| CU24534B1 (es) * | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
| CU20170173A7 (es) * | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
| CN109865137A (zh) * | 2019-01-23 | 2019-06-11 | 天德悦（北京）生物科技有限责任公司 | 经碘代乙酰基活化的琼脂糖微球在提高多肽或蛋白类免疫原免疫原性中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4857637A (en) * | 1986-05-07 | 1989-08-15 | Genentech, Inc. | Methods and compositions for immunologically modulating growth hormone receptor activity |
| IT1206250B (it) * | 1987-02-18 | 1989-04-14 | Ist Farmacoterapico It Spa | Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla- |
| US5726292A (en) * | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
| WO1994001133A1 (en) | 1992-07-08 | 1994-01-20 | Schering Corporation | Use of gm-csf as a vaccine adjuvant |
| CA2137638C (en) * | 1993-12-09 | 1999-07-20 | Ana M. V. Lopez | Anti gangliosides monoclonal antibodies and their use in the specific active immunotherapy of malignant tumors |
| CU22420A1 (es) | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
| US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| AU737330B2 (en) * | 1998-01-16 | 2001-08-16 | Biomira Usa Inc. | Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes |
-
2001
- 2001-11-29 PE PE2001001202A patent/PE20020572A1/es not_active Application Discontinuation
- 2001-12-05 AR ARP010105662A patent/AR031638A1/es not_active Application Discontinuation
- 2001-12-06 EA EA200300640A patent/EA005138B1/ru not_active IP Right Cessation
- 2001-12-06 US US10/003,463 patent/US7776342B2/en active Active
- 2001-12-06 EP EP01999387A patent/EP1356822B1/en not_active Expired - Lifetime
- 2001-12-06 CA CA2431188A patent/CA2431188C/en not_active Expired - Lifetime
- 2001-12-06 AU AU2151902A patent/AU2151902A/xx active Pending
- 2001-12-06 AT AT01999387T patent/ATE485833T1/de active
- 2001-12-06 DE DE60143363T patent/DE60143363D1/de not_active Expired - Lifetime
- 2001-12-06 WO PCT/CU2001/000010 patent/WO2002045746A2/es active IP Right Grant
- 2001-12-06 DK DK01999387.2T patent/DK1356822T3/da active
- 2001-12-06 JP JP2002547529A patent/JP4210519B2/ja not_active Expired - Lifetime
- 2001-12-06 CN CNB018215602A patent/CN1291755C/zh not_active Expired - Lifetime
- 2001-12-06 BR BR0116013-3 patent/BRPI0116013B8/pt not_active IP Right Cessation
- 2001-12-06 KR KR1020037007634A patent/KR100850473B1/ko active IP Right Grant
- 2001-12-06 MX MXPA03005032A patent/MXPA03005032A/es active IP Right Grant
- 2001-12-06 AU AU2002221519A patent/AU2002221519B2/en not_active Expired
- 2001-12-06 UY UY27059A patent/UY27059A1/es unknown
-
2003
- 2003-06-04 NZ NZ526282A patent/NZ526282A/en not_active IP Right Cessation
- 2003-06-05 ZA ZA200304411A patent/ZA200304411B/en unknown
-
2004
- 2004-08-30 HK HK04106497A patent/HK1063726A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03005032A (es) | 2004-09-10 |
| CN1291755C (zh) | 2006-12-27 |
| AU2151902A (en) | 2002-06-18 |
| DE60143363D1 (de) | 2010-12-09 |
| CA2431188C (en) | 2010-09-07 |
| ATE485833T1 (de) | 2010-11-15 |
| JP4210519B2 (ja) | 2009-01-21 |
| AU2002221519B2 (en) | 2006-11-23 |
| KR100850473B1 (ko) | 2008-08-07 |
| EP1356822A2 (en) | 2003-10-29 |
| EP1356822B1 (en) | 2010-10-27 |
| BRPI0116013B8 (pt) | 2021-05-25 |
| NZ526282A (en) | 2005-01-28 |
| CN1484532A (zh) | 2004-03-24 |
| EA200300640A1 (ru) | 2003-12-25 |
| DK1356822T3 (da) | 2011-02-07 |
| WO2002045746A3 (es) | 2002-12-27 |
| EA005138B1 (ru) | 2004-12-30 |
| KR20030061838A (ko) | 2003-07-22 |
| WO2002045746A2 (es) | 2002-06-13 |
| US7776342B2 (en) | 2010-08-17 |
| HK1063726A1 (en) | 2005-01-14 |
| ZA200304411B (en) | 2004-07-29 |
| JP2004523494A (ja) | 2004-08-05 |
| BRPI0116013B1 (pt) | 2018-07-24 |
| US20020136735A1 (en) | 2002-09-26 |
| UY27059A1 (es) | 2002-04-26 |
| BR0116013A (pt) | 2004-01-06 |
| CA2431188A1 (en) | 2002-06-13 |
| AR031638A1 (es) | 2003-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020572A1 (es) | Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos | |
| CY1112105T1 (el) | Ανοσογονα βακτηριακα κυστιδια με πρωτεϊνες εξωτερικης μεμβρανης | |
| UY25877A1 (es) | Antígenos estreptococo | |
| EP2275552A3 (en) | Neisserial antigenic peptides | |
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| EA200901060A1 (ru) | Новый способ и композиции | |
| NO20062044L (no) | Piscirickettsia salmonis-antigener og anvendelse derav | |
| ATE522541T1 (de) | Bakterielle adhäsine konformere | |
| CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
| AR033980A1 (es) | Antigeno de estreptococos | |
| ES2663872T3 (es) | Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria | |
| UA97092C2 (ru) | T-клеточные эпитопы с раково-эмбрионального антиген-незрелого рецепторного белка ламинина и их медицинское применение | |
| RU2012126328A (ru) | Вакцина против пневмонии, вызываемой streptococcus pneumoniae, на основе гибридного белка | |
| Leng et al. | Recombinant bacterial lipoproteins as vaccine candidates | |
| Cho et al. | Extracellular vesicle-associated antigens as a new vaccine platform against scrub typhus | |
| Kunjantarachot et al. | Effective platform for the production of recombinant outer membrane vesicles in gram-negative bacteria | |
| ATE493146T1 (de) | Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren | |
| PE20010239A1 (es) | Gen derivado de lawsonia y polipeptidos, peptidos y proteinas de hemolisina relacionados y sus usos | |
| ES2573105T3 (es) | Secuencias de péptidos y composiciones | |
| CU23009A1 (es) | Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos | |
| AR030292A1 (es) | Una proteina gapc; su metodo de produccion y su uso; un polinucleotido aislado y su uso; un vector recombinante; una celula huesped; una composicion de vacuna y su metodo de produccion; anticuerpos y sus usos; y un kit de inmunodiagnostico | |
| AR042237A1 (es) | Obtencion de estructuras cocleares, composiciones vacunales, adyuvantes y sus intermediarios | |
| Mostafavi-Pour et al. | Molecular cloning, expression, and purification of a recombinant fusion protein (rNT-gp96-NT300) | |
| BRPI0100837B8 (pt) | sequência de dna que codifica a proteína externa de membrana antigênica e específica de salmonella typhi | |
| KR20120000427A (ko) | 신규한 헤모필루스 파라수이스(ｈａｅｍｏｐｈｉｌｕｓ ｐａｒａｓｕｉｓ)항원 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |